Go Pro
NASDAQ:IRON

Disc Medicine (IRON) Stock Price, News & Analysis

Disc Medicine logo
$66.09 -2.39 (-3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$66.20 +0.11 (+0.17%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Disc Medicine Stock (NASDAQ:IRON)

Advanced

Key Stats

Today's Range
$65.31
$68.95
50-Day Range
$66.09
$82.67
52-Week Range
$40.00
$99.50
Volume
541,829 shs
Average Volume
541,053 shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$110.18
Consensus Rating
Moderate Buy

Company Overview

Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving red blood cell production, iron metabolism and related biological pathways, with the goal of addressing conditions that often have limited treatment options.

Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule inhibitor of glycine transporter 1. The company is evaluating bitopertin in diseases including erythropoietic protoporphyria, a rare disorder characterized by abnormal accumulation of protoporphyrin that can cause severe sensitivity to sunlight. Its pipeline also includes DISC-0974, an investigational antibody designed to target hemojuvelin and regulate hepcidin, a hormone involved in iron metabolism, for potential use in anemia associated with chronic disease and other hematologic conditions.

Founded in 2017, Disc Medicine is headquartered in Waltham, Massachusetts. The company’s programs are in clinical development and are being evaluated through studies conducted in the United States and other regions. Disc Medicine is led by John Quisel, who serves as president and chief executive officer.

AI Generated. May Contain Errors.

Disc Medicine Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

IRON MarketRank™: 

Disc Medicine scored higher than 41% of companies evaluated by MarketBeat, and ranked 621st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Disc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Disc Medicine has a consensus price target of $110.18, representing about 66.7% upside from its current price of $66.09.

  • Amount of Analyst Coverage

    Disc Medicine has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Disc Medicine's stock forecast and price target.
  • Earnings Growth

    Earnings for Disc Medicine are expected to decrease in the coming year, from ($6.61) to ($7.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Disc Medicine is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Disc Medicine is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Disc Medicine has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Disc Medicine's valuation and earnings.
  • Percentage of Shares Shorted

    199.54% of the float of Disc Medicine has been sold short.
  • Short Interest Ratio / Days to Cover

    Disc Medicine has a short interest ratio ("days to cover") of 16.63, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Disc Medicine has recently increased by 0.31%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Disc Medicine does not currently pay a dividend.

  • Dividend Growth

    Disc Medicine does not have a long track record of dividend growth.

  • News Sentiment

    Disc Medicine has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Disc Medicine this week, compared to 8 articles on an average week.
  • Search Interest

    Only 2 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,930,940.00 in company stock.

  • Percentage Held by Insiders

    3.76% of the stock of Disc Medicine is held by insiders.

  • Percentage Held by Institutions

    83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Disc Medicine's insider trading history.
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IRON Stock News Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
See More Headlines

IRON Stock Analysis - Frequently Asked Questions

Disc Medicine's stock was trading at $79.41 on January 1st, 2026. Since then, IRON shares have decreased by 16.8% and is now trading at $66.09.

Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($1.54) earnings per share for the quarter, topping analysts' consensus estimates of ($1.71) by $0.17.

Disc Medicine (IRON) raised $105 million in an IPO on Wednesday, August 12th 2020. The company issued 10,500,000 shares at a price of $10.00 per share.

Top institutional shareholders of Disc Medicine include BlackRock Inc. (6.47%), Wellington Management Group LLP (45.41%), Opaleye Management Inc. (22.29%) and Palo Alto Investors LP (10.88%). Insiders that own company stock include Venture Fund X LP Atlas, Orbimed Advisors Llc, John D Quisel, Mona Ashiya, Pamela Stephenson, William Jacob Savage, Jean M Franchi, Jonathan Yen-Wen Yu, Rahul Khara, Kevin Bitterman, Joanne Bryce and William Richard White.
View institutional ownership trends
.

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL).

Company Calendar

Last Earnings
7/30/2026
Today
9/23/2026
Next Earnings (Estimated)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IRON
CIK
1816736
Fax
N/A
Employees
165
Year Founded
2017

Price Target and Rating

High Price Target
$153.00
Low Price Target
$83.00
Potential Upside/Downside
+66.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$212.18 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-37.17%
Return on Assets
-33.65%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
24.14
Quick Ratio
24.14

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$19.52 per share
Price / Book
3.39

Miscellaneous

Outstanding Shares
38,390,000
Free Float
36,949,000
Market Cap
$2.54 billion
Optionable
Not Optionable
Beta
0.97

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:IRON) was last updated on 9/23/2026 by MarketBeat.com Staff.
From Our Partners